Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~* Adult subjects with previously treated recurrent CLL who have measurable lymphadenopathy~* Require therapy for CLL~* Have experienced CLL progression \< 24 months since the completion of the last prior therapy~* Currently not sufficiently fit to receive cytotoxic therapy because of chemotherapy-induced bone marrow damage or comorbidities.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Idelalisib + rituximab (Type: ACTIVE_COMPARATOR): Participants will receive idelalisib plus rituximab
- Placebo + rituximab (Type: PLACEBO_COMPARATOR): Participants will receive placebo to match idelalisib plus rituximab

Based on this trial design, predict the completion outcome and termination type (if applicable).